ClinicalTrials.gg
CompletedNCT02807909Updated Sep 12, 2016

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

A Phase 1 interventional study of BMS-986177 and Itraconazole in Thrombosis, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-12.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
12th of 19
28 · median 42
Started
2016
with 3 others
Phase 1
13 of 19
none open now
Registered
9th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 12th largest by enrollment, is one of 4 that started in 2016, is one of 13 in phase 1, and was the 9th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

The study is being conducted to assess the effects of co-administration of itraconazole or diltiazem, respectively, on the pharmacokinetic (PK) parameters Cmax, AUC(INF), and AUC(0-T) of BMS-986177

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Target population: Healthy subjects as determined by medical history, surgical history, physical examination, vital signs, (ECG), and clinical laboratory determinations.
  3. Subjects with of 18 to 30 kg/m2, inclusive
  4. Men, and women of nonchildbearing potential. Women must have documented proof that they are not of and are not breast feeding
  5. Males who are sexually active with women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of for the duration of treatment with study drug(s) plus 5 half-lives of the study drug (3 days) plus 90 days (duration of sperm turnover) for a total of 92 days for subjects in the BMS-986177 - diltiazem sequence, and 99 days for subjects in the BMS-986177 - itraconazole sequence.

Exclusion criteria

Exclusion Criteria:

  1. Any significant acute or chronic medical illness, including hepatic disease, or any other condition listed as a in the diltiazem or itraconazole package inserts.
  2. Evidence of coagulopathy, prolonged or unexplained bleeding, or frequent unexplained bruising or thrombus formation.
  3. History of chronic constipation, GI disease, arrhythmias, sinus bradycardia, significant head injury, dizziness or headaches, hemophilia, Rosenthal syndrome, or FX1a deficiency or other coagulopathies, systemic lupus erythematosus.
  4. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, , or clinical laboratory determinations beyond what is consistent with the target population
  5. History of allergy to BMS-986177, itraconazole, diltiazem, or related compounds.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    BMS-986177 and Itraconazole

    Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days

    Drug: BMS-986177 · Drug: Itraconazole

  • Experimental
    BMS-986177 and Diltiazem

    Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days

    Drug: BMS-986177 · Drug: Diltiazem ER

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC (0-T)) of BMS-986177

    Time frame: Days 1-12

  2. Maximum observed concentration (Cmax)

    Time frame: Days 1-12

  3. Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Days 1-12

Secondary outcomes

  1. Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death

    Time frame: Screening- until 30 days after discontinuation of dosing or subject's participation in the study if the last scheduled visit occurs at a later time.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Perera V, Wang Z, Lubin S, Christopher LJ, Chen W, Xu S, Seiffert D, DeSouza M, Murthy B. Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. Cardiol Ther. 2022 Sep;11(3):407-419. doi: 10.1007/s40119-022-00266-6. Epub 2022 May 31. PubMed 35641780 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jun 21, 2016
Start
Jul 2016
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Sep 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02807909
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jul 2016
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Sep 12, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion